Stock Ratings / Health Care / ATHE / options

GRCE (35) ALDX (50) DWTX (41) GRDX (26) ⌘ Pro Terminal →

Alterity Therapeutics Limited (ATHE) Options Positioning, Max Pain & Unusual Sweeps

Q: Is ATHE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Alterity Therapeutics Limited (NASDAQ: ATHE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $2.23 (+2.93% 1D, market cap $40.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ATHE ranks #237 in composite RQD confidence.

Q: How does ATHE compare to GRCE and ALDX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATHE carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GRCE (Grace Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -18.9%, cap $40.8M) and ALDX (Aldeyra Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $39.8M). Among the 5-stock peer group, ATHE leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for ATHE?

For Alterity Therapeutics Limited (ATHE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #237 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is ATHE trading relative to its 50-day, 200-day, and 52-week technical levels?

ATHE last traded at $2.23 (+2.93% on volume of 3,791 shares), positioning the stock -36.29% below its 50-day simple moving average ($3.50) and -43.97% below its 200-day simple moving average ($3.98). Across its 52-week range of $2.01 to $5.89, ATHE sits at the 5.7% percentile with a 14-day RSI of 25.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.95 to $2.51).

Q: What is ATHE's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ATHE.

$2.23 +2.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.24

Alterity Therapeutics Limited (ATHE) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $40.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.24 (+0.34%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATHE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY ATHE SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (22% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 25.6 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$3.12-16% Next Q

Q2 (-2Q)

Grade C+$2.62-20.2% Next Q

Q3 (-1Q)

Grade C$2.09+6.7% Next Q

Current

Grade D+$2.23+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ATHE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, ATHE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.50) or 200D SMA ($3.98) invalidates the momentum regime and cuts Target Base ($2.23) toward Bear Floor ($1.74).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATHE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATHE Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ATHE)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ATHE.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATHE)

✓Walkthrough of ATHE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATHE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.88%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.23H $2.24L $2.11C $2.23VOL 9.1K

RES: $3.92SUP: $1.87SMA50: $3.50SMA200: $3.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATHE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATHE Butterfly Map → + Track ATHE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ATHE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATHE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATHE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATHE)

Health Care Rank #237 of 1016 ⚔️ GRCE vs ATHE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATHE vs. GRCE, ALDX, DWTX, GRDX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alterity Therapeutics Limited (ATHE) ranks #237 by composite RQD confidence (58/100, grade D+) and #774 by equity capitalization ($40.7M). Within this direct 5-issuer industry benchmark cohort, ATHE leads on earnings valuation at N/A trailing P/E, while GRCE leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. ATHE currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATHE ACTIVE Alterity Therapeutics Limited	D+	58/100	—	—	—	+2.93%	$40.7M	Benchmark Subject
GRCE Grace Therapeutics Inc.	D-	35/100	—	—	-18.9%	-3.48%	$40.8M	/grce-vs-athe →
ALDX Aldeyra Therapeutics Inc.	D	50/100	—	—	-35.0%	-3.58%	$39.8M	/aldx-vs-athe →
DWTX Dogwood Therapeutics Inc.	D-	41/100	—	—	-32.3%	-0.81%	$41.8M	/dwtx-vs-athe →
GRDX GridAI Technologies Corp.	E	26/100	—	-30.0%	-20.0%	-5.38%	$38.9M	/grdx-vs-athe →

2. ATHE Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Alterity Therapeutics Limited (ATHE) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $40.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ATHE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATHE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Alterity Therapeutics Limited (NASDAQ: ATHE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $2.23 (+2.93% 1D, market cap $40.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ATHE ranks #237 in composite RQD confidence.

How does ATHE compare to GRCE and ALDX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATHE carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GRCE (Grace Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -18.9%, cap $40.8M) and ALDX (Aldeyra Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $39.8M). Among the 5-stock peer group, ATHE leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ATHE?

For Alterity Therapeutics Limited (ATHE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #237 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ATHE trading relative to its 50-day, 200-day, and 52-week technical levels?

ATHE last traded at $2.23 (+2.93% on volume of 3,791 shares), positioning the stock -36.29% below its 50-day simple moving average ($3.50) and -43.97% below its 200-day simple moving average ($3.98). Across its 52-week range of $2.01 to $5.89, ATHE sits at the 5.7% percentile with a 14-day RSI of 25.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.95 to $2.51).

ATHE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ATHE's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ATHE.

Direct Sub-Reports: ATHE RQD Cockpit ATHE 12M Forecast ATHE Earnings & Move ATHE Dividends & DRIP ATHE Insiders & 13F ATHE Whale Options ATHE Profit Sankey ATHE News & Why